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Abstract
The use of DNA to deliver vaccine antigens offers many advantages, including ease of
manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial
culture, necessitating elements which are either unnecessary for effective gene delivery (e.g.
bacterial origins of replication) or undesirable (e.g. antibiotic resistance genes). Removing these
elements may improve the safety profile of DNA for the delivery of vaccines. Here we describe a
novel, double-stranded, linear DNA construct produced by an enzymatic process that solely
encodes an antigen expression cassette, comprising antigen, promoter, polyA tail and telomeric
ends. We compared these constructs (called ‘Doggybones’ because of their shape) with
conventional plasmid DNA. Using luciferase-expressing constructs, we demonstrated that
expression levels were equivalent between Doggybones and plasmids both in vitro and in vivo.
When mice were immunized with DNA constructs expressing the HIV envelope protein gp140,
equivalent humoral and cellular responses were induced. Immunizations with either construct type
expressing haemagluttinin were protective against H1N1 influenza challenge. This is the first
example of an effective DNA vaccine which can be produced on a large scale by enzymatic
processes.
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Introduction
In the 1990s it was demonstrated that when antigen-encoding nucleic acid is introduced into
the body it can invoke an immune response against the encoded antigen(1). DNA vaccines
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have many advantages over traditional strategies: they are relatively safe compared to
attenuated vaccines, they are stable and can be stored frozen or lyophilized, they are easy to
manufacture and can stimulate cell mediated immune responses(2). Whilst there are DNA
vaccines licensed for veterinary use(3) and DNA vaccines have been shown to be effective in
numerous models, currently there are no DNA vaccines licensed for human use(4, 5). The
main hurdle has been poor immunogenicity in humans and but there are also concerns over
genomic integration and induced allergy to DNA. However the FDA has recently relaxed its
regulations regarding the latter two points(6).
Conventionally DNA vaccines are produced as plasmids grown in genetically modified
bacteria, normally Escherichia coli. Such plasmids must contain, alongside the gene of
interest, a bacterial origin of replication and a selective gene, normally encoding antibiotic
resistance, to maintain the persistence of the plasmid in the bacterium(7). Whilst DNA
vaccines have proven to be safe in a number of animal models and early phase clinical trials,
there is a concern that the antibiotic resistance genes in the DNA vaccine may be conveyed
to pathogenic bacteria or microflora. The use of antibiotic resistance genes has previously
been negated through the use of RNAi ‘RNA-OUT’ as a counter selectable marker or
auxotrophic selection(8, 9). Such methods can increase production efficiency by decreasing
the metabolic burden on the bacteria(10). However the reliance on bacteria as a method to
produce the vaccine means there is a small chance of recombination events within the
plasmid, leading to the loss of the antigenic determinant(11). To avoid problems with
recombination events, extensive quality controls at a molecular level need to be installed on
a batch by batch basis. Additionally, the presence of endotoxin within the system means
that, after extraction, DNA must be cleaned and further quality control (QC) measures
applied(12).
The use of minimal DNA constructs for example minicircles, small circular fragments of
DNA derived from a larger plasmid(13) or minimalistic immunologically defined expression
(MIDGE) vectors(14), that only encode an antigen expression cassette (promoter, antigen and
polyA region), goes some the way to solve the problem of extraneous elements. These
vectors have been shown to be immunogenic, inducing both a cellular and humoral
response, but both of these vectors require a bacterial fermentation step(15). Synthesizing the
vaccine entirely in vitro, with the absence of a bacterial step, would ensure uniformity
between batches and increase their readiness for good manufacturing practice (GMP)
production. Recently the molecular tools by which to do this have become available in the
form of enzymes derived from bacteria and bacteriophages. Using a proprietary method
from Touchlight Genetics, covalently closed linear DNA constructs can be made
synthetically which permits rapid vaccine design and manufacture. The DNA vectors
produced by the process are referred to as ‘Doggybones’ (DB) due to their proposed shape
and are synthesized in controlled batch reactions.
The aim of this study was to characterize Doggybone constructs for use as DNA vaccines
and to compare them to plasmids. We demonstrated that Doggybones are comparable to
conventional plasmids in terms of expression and immunogenicity. This study therefore
concludes that Doggybones could be a suitable replacement for plasmid DNA for gene
delivery in the context of DNA vaccines.
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Results
Production of linear closed DNA construct
Linear DNA constructs were produced using the outlined mechanism (Fig. 1A)(16). The
process is composed of two steps; firstly plasmid DNA which has the sequence for the
antigen flanked by telRL sites is amplified by rolling circle replication using phi29 DNA
polymerase from Bacillus subtilis phage phi29, resulting in the production of long
concatamers. The protelomerase TelN (from E. coli phage N15) then cleaves the
concatamers into strands containing a single cassette and seals the ends with a short hairpin
loop(17). The constructs are composed of a linear double stranded region with an antigen
expression cassette, encoding the sequences for the CMV Immediate Early promoter plus
enhancer, the gene of interest and the SV40 late poly A tail, flanked by single stranded
telomere ends (Fig. 1B). In the initial round of amplification, plasmid DNA is used as a
template, but this is then selectively digested with restriction enzymes and then exonuclease
III. In subsequent rounds of amplification the Doggybone itself can be used as the template.
To confirm that hairpin loops had formed, DNA migration was compared on denaturing or
native gels. A representative Doggybone construct (DB GL derived from pGL DOG
containing a luciferase cassette) was compared with linear DNA (PCR GL) encoding the
same sequence but derived through PCR. The only structural difference is that the
Doggybones contain covalently closed telomere ends whereas the PCR products contained
open ends. On the native gel the constructs migrated at a similar speed reflecting the
similarity in size (2.4 kb for DB GL and 2.7kb for PCR GL) (Fig. 1C). However, on a
denaturing gel the Doggybone became a large open single stranded circular structure and
thus appeared larger than the equivalent linear PCR construct which became single DNA
strands (Fig. 1D). A similar observation was made when a plasmid containing the telRL sites
was linearised by protelomerase TelN - resulting in hairpin ended DNA or restriction
endonuclease - resulting in open ended DNA (Fig. 1C-D).
The plasmid and Doggybone constructs that were used in subsequent imaging studies, were
characterized using dynamic light scattering over a pH gradient. Both plasmid and
Doggybone show similar trends and were at their largest (Fig. 1E) and most cationic (Fig.
1F) at low pH. They became more condensed and more negatively charged as the solution
became more basic. The two constructs behaved remarkably similarly given the differences
in structure and molecular weight.
Comparative expression from Plasmid or Doggybone constructs
To compare expression levels we made plasmid and Doggybone constructs that encoded the
firefly luciferase gene and transfected CHO-K1 cells. In tests to compare delivery of both
DNA constructs by electroporation, both the Doggybone and the plasmid were transfected
with equal efficiency (Fig. 2A). Due to the novelty of the Doggybone structure we wished to
determine whether there were differences in the mechanisms by which transfection reagents
package the DNA. We compared a liposome formulation (Lipofectamine), a polycationic
complex formulation (PEI) and a branched dendrimer formulation (Polyfect). We reasoned
that, having been optimized for circular supercoiled plasmids, the reagents may compact
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linear DNA constructs differently, leading to complexes with differing physical parameters
and capacity to transfect. While Lipofectamine and Polyfect have manufacturer optimized
protocols, PEI mediated transfection was optimized to balance nitrogen to phosphate ratios,
an 8:1 PEI:DNA ratio gave optimum expression with both constructs (data not depicted).
We observed comparable levels of expression of luciferase with Doggybone and plasmid
with either Lipofectamine (Fig. 2B) or PEI (Fig. 2C) but when Polyfect was used as the
transfection reagent, plasmid DNA had significantly higher transfection efficiency then
Doggybone at 48 hours (p<0.01, Fig. 2D). To define why different reagents behaved
differently, we measured the size (Fig. 2E) and charge (Fig. 2F) of the DNA-transfection
reagent complexes using dynamic light scattering. Lipofectamine-plasmid constructs had a
significantly more negative charge than Lipofectamine-Doggybone constructs (p<0.01), but
this appears not to alter the capacity to transfect cells, however Polyfect-plasmid constructs
were significantly larger (p<0.01) than Polyfect-Doggybone constructs suggesting, for this
reagent, the secondary structure of DNA had an important role. We wished to confirm the
expression data using a different gene readout system and observed similar transfection
efficiency between Doggybone and plasmids expressing the red-fluorescent protein
tdTomato (Supp Fig. 1).
Having validated gene expression from Doggybones in vitro we sought to confirm these
observations in vivo. To this end mice were immunized with luciferase-expressing
constructs intramuscularly (IM) with electroporation. Light emitted after intraperitoneal
luciferin injection was measured by in vivo imaging and images overlaid with X-ray images
of the same animals to indicate the position of expression, background photon detection was
eliminated by the concurrent imaging of control, untransfected animals (Supp. Fig 2).
Luciferase gene expression was detectable in vivo from both the plasmid and the Doggybone
constructs (Fig. 3A). Relative expression levels were quantified and there were no
significant differences between Doggybone and plasmid (Fig. 3B), however there was a
trend for reduced expression from the Doggybone constructs on day 7. Since Doggybones
are smaller than plasmid DNA, in a mass-matched study, more gene copies are introduced,
therefore we compared mass and molarity matched in vivo luciferase expression from the
two constructs (Fig. 3C). There was a trend towards reduced expression in expression after
Doggybone transfection compared to the molarity matched plasmid group. In these studies
we show that genes were expressed from Doggybones and plasmid at comparable levels in
vitro and in vivo.
Comparative immunogenicity of Plasmid and Doggybone expressed antigens
To test the immunogenicity of Doggybone delivered genes, HIV clade C MWS2 gp140 (the
envelope protein gp120 and the transmembrane protein gp41(18)) and haemagluttinin (HA)
from H1N1 influenza (A/England/195/2009) were chosen as model antigens. For the HIV
gp140 studies we used a prime boost regime of four intramuscular DNA immunizations with
electroporation two weeks apart followed by a single intramuscular protein boost.
Electroporation was used as it gives a significantly enhanced response to in vivo DNA
delivery(19, 20). All immunizations were well tolerated and no adverse reactions were
observed.
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Both Doggybone and plasmid groups developed comparable gp140 specific IgG levels with
the group mean at 734 and 675 ng/ml respectively; these were significantly greater than the
group receiving protein alone but not significantly different from each other (Fig. 4A).
Interestingly, it was only after the protein boost that an antibody response could be detected.
Cellular responses against peptide pools comprising peptides derived from the N terminus
(pool 1) or C terminus (pool 2) of CN54 gp140 were measured using Interferon γ (IFNγ)
secretion as a readout. As with humoral responses, we observed a comparable cellular
response to both the Doggybone and the plasmid. The plasmid group had an average of 191
and 306 IFNγ spot forming units (SFU) for peptide pools 1 and 2 respectively whilst the
Doggybone group had an average of 154 and 280 SFU (Fig. 4B), there were negligible
amounts of cells secreting IFNγ in the PBS primed group, two animals were excluded from
the Doggybone group because the ELISPOT wells were too numerous to count.
DNA constructs expressing influenza haemagluttinin (HA) were tested for their ability to
protect mice from challenge with a homologous H1N1 influenza strain (A/England/
195/2009). Mice received three intramuscular DNA immunizations with electroporation two
weeks apart prior to intranasal infection with H1N1. Pre challenge HA specific IgG could be
detected in both the DNA vaccinated groups but not in the control group (Fig. 4C). The
Doggybone and plasmid protected animals from weight loss after infection whereas the PBS
control group lost significantly more weight at days 6 and 7 after infection (p<0.01, Fig.
4D). Virus could be recovered from the lungs of every mouse in the group receiving PBS
whereas no virus could be isolated from the lungs of animals receiving either DNA construct
signifying protection (Fig. 4E). After challenge there were higher levels of HA specific lung
IgA in the Doggybone and plasmid groups than the PBS control group (Fig. 4F). We show
that the Doggybone and the plasmid DNA both induce an immune response to antigen and
when used as a vaccine can protect from viral infection.
Discussion
The objective of this study was to compare closed linear DNA generated through enzymatic
processes with circular, bacterially derived plasmids, for use as DNA vaccines. In this study
we did not observe any difference between the expression levels of luciferase when
delivered as a Doggybone or a plasmid. Whilst we studied the role of Doggybones as DNA
vaccines, the equivalence in expression levels with plasmid suggest that these constructs
could also be used for other gene delivery purposes. There are several factors that contribute
to the expression levels from transfected DNA constructs, these include construct size(21, 22),
DNA topology with linear DNA transfecting less well than supercoiled plasmid(23), and the
number of CpG motifs affecting the time it takes for the immune system to recognize and
thus clear the transfected cells(24-26). The equivalence in response between the Doggybone
and plasmid reflects the balance between a number of these factors. For example whilst
Doggybones contain less DNA per unit weight as plasmids, they occupy the same space in
physiological environments probably due to supercoiling of the plasmids. Differences were
observed between Polyfect (based upon dendrimers complexing the DNA) and the charged
reagents, PEI and Lipofectamine, which may reflect the differences in charge and structure
of the plasmid and Doggybone. Another linear minimal construct, the MIDGE vector, also
has comparable expression in vitro and in vivo as plasmid DNA(14, 27). Future work will
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investigate formulating Doggybone to improve expression levels, for example formulating
with PEI(28, 29) as has previously been performed with minicircles(30, 31).
We also observed an equivalent immune response to antigens expressed from either
Doggybone or plasmid. Using influenza challenge we were able to demonstrate that the
immune response to DNA vaccine alone was protective and that there were no differences
between plasmid and Doggybone. Immunization induced both a cellular and a humoral
response, though for the HIV antigen, protein boosting was required for an antibody
response. In part, the poor antibody response to the gp140 vaccination may be due to the
ELISA assay which, due to reagent availability, was coated with a different clade C gp140 –
CN54 to the vaccine antigen MWS2, reducing the sensitivity. However, it has been
previously observed that DNA vaccines induce a better cellular response than humoral
response and we observed a strong cellular response in our studies. The use of DNA
vaccines in humans has so far had limited success, with poor translation from pre-clinical
models to clinical trials. However, the use of electroporation as in the current study has been
shown to considerably improve the immunogenicity of a DNA vaccine(19). Increased
immunogenicity with electroporated DNA vaccines is associated with increased expression
of the delivered DNA(20) and potentially also increased inflammation due to the tissue
damage after the application of the electric field(32).
Until now the most promising candidates for minimal DNA constructs were minicircles.
These are circular plasmids containing only the gene of interest and the necessary regulatory
elements which are excised from a larger parental plasmid grown in bacteria(13). MIDGE
vectors are probably the second most prominent candidate, comprised of linear constructs
sealed with hairpin loops that are derived from a plasmid with restriction endonucleases and
sealed enzymatically(33). While these constructs address many of the concerns outlined by
the FDA, such as integration, allergy and the presence of antibiotic resistance genes, the fact
that they are still produced in bacterial represents a potential regulatory concern(34). Here we
describe a third candidate minimal DNA construct for gene delivery, which does not require
a bacterial production step – “Doggybone” DNA. In much the same way as PCR allowed for
amplification of specific DNA through the actions of enzymes, the Doggybone process
allows for the production, en masse, of GMP standard DNA constructs for use as gene
delivery vectors from a template.
Methods
DNA constructs
The proTLx expression plasmid consisted of the CMV Immediate early promoter plus
enhancer, a multiple cloning site and an SV40 late polyadenylation signal all flanked by two
telRL sequences, the site of protelomerase TelN recognition and cleavage. The plasmid
backbone contained an ampicillin resistance gene and the pUC origin of replication. The
Luciferase gene from Photinus pyralis (firefly), the gene encoding gp140 from HIV-1 Clade
C MSW2 and the haemagluttinin gene from H1N1 Influenza (A/England/195/2009) were
cloned (including a GCCACC Kozak sequence) into the HindIII and EcoRI sites on the
proTLx base plasmid by restriction digest. Plasmids were maintained in recombination
deficient E. coli strains. For use in vivo, plasmid was prepared from E. coli using an
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EndoFree Giga kit (Qiagen). Recombinant plasmids were verified by restriction
endonuclease digestion and sequencing.
Purification of TelN protelomerase
The gene encoding protelomerase TelN, from E. coli phage N15, was cloned into pQE-30
UA (Qiagen) under the control of the IPTG-inducible promoter from phage T5. The enzyme
was overproduced in E. coli M15 pREP4 cells (Qiagen), with an N-terminal 6 X Histidine
tag, and purified on a HisTrap column (GE Healthcare) using a linear gradient of imidazole
(0-500mM) and standard purification techniques. The eluted protein was buffer exchanged
into 10mM Tris HCl pH 7.4, 75mM NaCl, 50% (v/v) glycerol, 1mM DTT & 0.1mM EDTA)
and stored at a concentration of 15μM at −20°C.
Preparation of closed linear DNA (Doggybones)
Plasmid was prepared using a miniprep kit (Qiagen) and used as a template for Rolling
Circle Amplification by the method described in patent EP2391731(16). The template
plasmid containing gene of interest flanked by telRL sites, was mixed with custom primers
(50μM) and the template denatured by heating to 95°C. To initiate rolling circle
amplification from the denatured template, the reaction was first mixed with reaction buffer
(30mM Tris-HCl pH 7.4, 5mM (NH4)2SO4, 30mM KCl, 7.5mM MgCl2, 2mM DTT) and
then 2mM dNTPs (Bioline) were added together with 2000 units of Phi29 DNA polymerase
(Lucigen) and 4 units of thermostable pyrophosphatase (Lucigen). Upon mixing, the
reaction was incubated at 30°C for 18 hours with custom primers (2μM) and 2mM dNTPs.
In order to produce Doggybones by cleaving at the telRL sites and capping the double
stranded ends, the protelomerase TelN (1μM) was added to the reaction and the reaction
mixture was incubated at 30°C for10 minutes. The amplified concatamers were processed by
adding 2X unit excess of ApaLI restriction enzyme (NEB) and 1.5 Molar excess amounts of
the single turnover TelN protelomerase. This cleaved the concatamers to produce
Doggybone DNA encompassing the expression cassette containing luciferase, gp140 or HA
and a second Doggybone consisting of the backbone components which was also cleaved by
ApaLI to produce 3 fragments. These backbone fragments were digested by the addition of
500U/mg DNA exonuclease III. The reaction was monitored until all the backbone
fragments had been removed by exonuclease. The Doggybone DNA was purified using
Cleanup Maxi columns (A&A Biotechnology, Gdynia, Poland), as manufacturer’s
instructions, and eluted into Tris EDTA buffer at pH8 or H2O. The resulting elutions were
concentrated using 50 MWCO Amicon columns to a final concentration of 1mg/ml.
DNA Hairpin assay
Two different telRL-containing plasmids were constructed to investigate the ability of TelN
to cleave DNA to produce the hairpin ends. The commercially available Luciferase-
encoding plasmid pGL4.13 (Promega) was modified to include 2 telRL sequences flanking
the Luciferase cassette. It was hereafter named pGL DOG with the Doggybone created from
this construct called DB GL. A PCR-amplified version of the pGL DOG cassette (PCR GL)
incorporating the telRL-flanked expression region was created. pUC18 telRL was created by
the addition of a telRL site into the HindIII and BamHI sites of pUC18 (Thermo Scientific).
Walters et al. Page 7
Gene Ther. Author manuscript; available in PMC 2015 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Doggybone and linear DNA constructs were run on native and denaturing gels. Native gel
100ng of each sample mixed with 6X gel loading buffer (Sigma) was run on a 0.8% agarose
in TAE gel run in 1xTAE. Denaturing gel 500ng of each sample was mixed with 6X
denaturing sample buffer (300mM NaOH, 6mM EDTA, 18% Ficoll, 0.15% bromocresol
green, 0.25% xylene cyanol). The samples were then run on a 1% agarose (in H2O) at 10V
in denaturing running buffer (50mM NaOH, 0.1mM EDTA) overnight on ice to minimize
overheating. Once sufficiently separated the gel neutralized for 30 min in 1M Tris HCl pH
7.6, 1.5M NaCl. Both gels were stained for DNA with ethidium bromide and visualized
under UV light.
DNA construct characterization by dynamic light scattering
DNA size and charge were calculated using dynamic light scattering on a Zetasizer Nano
(Malvern Instruments) in a disposable zeta cell. DNA or DNA complexes were first diluted
to 2 μg/ml in filter sterilized degassed water. Samples were read at 25 °C with a back scatter
set at 173°, the average of 20 readings in triplicate was taken in each case. Data was
analyzed using Malvern instruments Zetasizer software 7.01.
In vitro transfection
CHO-K1 cells were grown to 95% confluence in compete DMEM before being transfected
with 1ug of luciferase or tdTomato-expressing plasmid or Doggybone. DNA was delivered
by electroporation using a Nucleofector II device with cell line transfection kit T (Lonza) or
using the following transfection reagents; Lipofectamine 2000 (Invitrogen), Polyfect
(Qiagen) or PEI (Polysciences). Each was used according to supplier’s specification.
Luciferase expression: At the appropriate juncture, media was removed, cells were lysed
using luciferase lysis buffer (Promega) and frozen for 24 hours. Expression was visualized
after the addition of luciferase assay substrate (Promega) and light emission was read using
a FluorStar OPTIMA multilablel plate reader (BMG Labtech) and recorded as relative light
units (RLU). tdTomato red fluorescent protein expression was imaged using a Nikon Eclipse
TE2000-S inverted microscope under bright light and a TxRed filter set (excitation
540-580nm and emission 600-660nm) at 24 and 48 hours after transfection.
Animals
Female BALB/c mice were obtained from Harlan Scientific (Bevil’s Hill, UK) and used at
6-8 weeks of age. All procedures undertaken had been approved by the local ethics review
board and performed by personal licensees under the appropriate project license.
Experiments carried out were in accordance with Animals (Scientific Procedures) Act 1986.
DNA injections
Mice were injected intramuscularly (IM) into the anterior tibialis with 25μg plasmid or
Doggybone in 50μl of sterile PBS followed by electroporation (EP). Two lots of 5 pulses of
150V with switched polarity between pulses were delivered using a CUY21 EDIT system
(BEX, Japan). For the HIV gp140 immunisation study, mice received a prime boost regime
of four IM DNA immunizations with electroporation two weeks apart followed by a single
IM protein boost of CN54 gp140 protein (10 μg). For the influenza study, mice received
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three IM DNA immunizations with electroporation two weeks apart prior to infection with
H1N1.
In vivo imaging
After transfection with plasmid or Doggybone encoding luciferase, expression was
visualized using an In vivo FX pro (Carestream, USA) following intraperitoneal injection of
Rediject D-Luciferin (Caliper) in accordance with manufacturer’s specification. Light
emission was measured for 4 minutes without binning and an X-ray was taken for 30
seconds, the two images were overlaid using Carestream MI SE software. Relative
luminescence was quantified by using the software’s region of interest (ROI) analysis
function, with background levels set using control, untransfected animals.
Antigen specific ELISA
A quantitative assay was used to determine serum antibody levels adapted from Donelly et
al(35). 96-well plates were coated with 1μg/ml gp140 or HA1 (A/England/195/2009, Life
Technologies) and blocked with 1% BSA. A dilution series of recombinant murine IgG was
used on each plate as a standard to quantify antigen specific antibodies. Sera were diluted
1:500, 1:5,000 and 1: 50,000 to ensure the absorbance reading measured fell within the
linear range of the standard curve. Bound IgG was detected by incubation for 2 hr at 37 °C
with HRP-conjugated goat anti-mouse IgG (AbD Serotec). Plates were washed and
developed with 50 μl TMB/E substrate and the reaction was terminated by the addition of 50
μl of 2M H2SO4 and read at A450. For IgA measurements on lung mash supernatants, a
similar protocol was performed using biotinylated anti-IgA and detected using HRP-
Streptavidin, compared to a standard curve of recombinant murine IgA.
Cellular Assays
Splenocytes were isolated by mechanical dissociation through sterile nylon mesh, followed
by red blood cell lysis with ammonium chloride. The splenocytes were cultured for 72h at
2.5× 105 cells/well in the presence of HIV gp140 CN54 peptides divided into two pools as
has previously been described(29) and 2μg/ml anti CD28 (BD Pharmigen). Concanavalin A
(ConA, Sigma) and culture media were used as the positive and negative control
respectively. ELISPOT assays were performed using a commercial kit from MABTECH
(Nacka Strand, Sweden) following the manufacturer’s recommendations. The spots were
counted using the AID ELISPOT reader ELR03 (Autoimmune Diagnostika).
Influenza Infection
H1N1 Influenza strain (A/England/195/2009) was grown in Madin-Darby Canine Kidney
(MDCK) cells, in serum free DMEM supplemented with 1ug/ml trypsin. The virus was
harvested 3 days after inoculation and stored at −80°C. Viral titre and lung viral load
determined by plaque assay as previously described(36). Mice were infected intranasally
with 5×105 PFU virus. Weight was measured daily to monitor disease severity. The
harvesting of lung tissues was carried out as previously described(37). For the preparation of
lung mash supernatants, lungs were homogenized through 100 μm cell strainers (BD
Pharmingen) and washed through with a 1ml volume of RPMI five times, following
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centrifugation this supernatant was retained for viral load analysis. After the removal of the
supernatants from all tissues, cells were treated with ACK lysing buffer for 5 minutes and
they were resuspended in RPMI. Cell viability was assessed by trypan blue exclusion, and
total cell numbers were counted by disposable multiwell haemocytometer.
Statistical analysis
The appropriate statistical test was performed using GraphPad prism 5.01 (GraphPad
Software Inc, La Jolla, CA, USA). Based on the type of data either a 2 way ANOVA with
Bonferroni’s post test or a student’s T-test was performed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characterisation of Doggybone constructs
Doggybones were produced using the method outlined by(16), a summary of the process is
shown (A). Rolling circle replication takes place from a starting plasmid resulting in
concatamers which are then resolved through the actions of TelN on the telRL sites included
in the sequence. Addition of restriction enzymes and exonuclease removes any
contamination from the plasmid backbone sequences to leave the cassette Doggybone only.
The end product is a linear dsDNA construct flanked by ssDNA hairpins (Doggybones) (B).
To confirm the Doggybone structure constructs were run on a native (C) and a denaturing
agarose gel (D). The following were run: Doggybone DB GL (lane 1 created from pGL
DOG (Luciferase cassette)), the PCR GL insert only obtained through PCR (lane 2), pUC18
telRL plasmid linearised with TelN (lane 3) or XmnI (lane 4). The size (E) and charge (F) of
Doggybone (●) or plasmid (□) were assessed by dynamic light scattering, points represent
mean of n=3 +/− SEM.
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Figure 2. Doggybone and plasmid have similar expression levels in vitro
The efficiency of transfection of 1 μg Doggybone (●) or plasmid (□) encoding luciferase in
CHO-K1 using electroporation (A), Lipofectamine (B), PEI (C) or Polyfect (D) was tested.
Light emission was recorded as relative light units (RLU).The size (E) and the charge (F) of
complexes formed by each transfection reagent at pH 7 was characterised by dynamic light
scattering. Bars/points represent mean of n=3 replicates +/− SEM * p<0.05, **p<0.01,
***p<0.001, calculated using ANOVA and Bonferroni’s post test.
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Figure 3. In vivo Assessment of DNA construct expression levels
BALB/c mice (n=5) were injected IM with 25 μg μg Doggybone (●) or plasmid (□)
encoding luciferase with electroporation. At days 2, 3 and 7 after inoculation expression was
visualized using a Carestream in vivo imaging system after intraperitoneal injection of
Rediject luciferin, one representative image shown per time point (A). Luciferase levels
from n=22 animals were quantified as relative light units using the Carestream analysis
software (B), points represent individual mice, line represents mean +/− SEM. Mice were
injected with 50μg Doggybone and compared with mass-matched plasmid (50μg) or
concentration matched plasmid (85μg) expressing luciferase and expression measured by in
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vivo imaging over time (C), points represent mean of n=4 mice +/− SEM. ns denotes p>0.05
analysed by ANOVA and Bonferroni’s post test.
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Figure 4. In vivo immunogenicity assessment of DNA constructs expressing HIV gp140
BALB/c mice (n=5) were inoculated four times IM with electroporation with 25 μg gp140
encoding plasmid (□), Doggybone (●) or PBS (▲) as a negative control. At day 56 all
groups received 10 μg of recombinant gp140 IM. Serum was collected on day 70 and gp140
specific IgG levels were tested using ELISA (A). On day 70 splenocytes were taken and
restimulated with synthetic peptides representing the N (pool 1) or C (pool 2) terminus of
the gp140 protein, IFNγ was measured using ELISpot (B). BALB/c mice (n≥4) were
inoculated IM with electroporation three times with 25 μg influenza HA encoding plasmid
(□), Doggybone (●) or PBS (▲) as a negative control, at day 42 mice were infected with
105 PFU H1N1 influenza intranasally. Antibody titre was calculated on d41 prior to
infection (C). Weight loss was monitored following infection (D), lung viral load (E), and
lung IgA (F) were measured on day 7 after infection. Points represent individual animals,
lines represent mean +/− SEM, *p<0.05, **p<0.01, ***p<0.001, analysed by ANOVA and
Bonferroni’s post test. For panel D points represent mean of n=5 animals +/− SEM,
**p<0.01, ***p<0.001 Doggybone compared to PBS group, ##p<0.01, ###p<0.001,
Plasmid compared to PBS group.
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